About 4d molecular therapeutics inc - FDMT
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
FDMT At a Glance
4D Molecular Therapeutics, Inc.
5858 Horton Street
Emeryville, California 94608
| Phone | 1-510-505-2680 | Revenue | 85.21M | |
| Industry | Biotechnology | Net Income | -140,109,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 230,194.595% | |
| Fiscal Year-end | 12 / 2026 | Employees | 196 | |
| View SEC Filings |
FDMT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.099 |
| Price to Book Ratio | 0.854 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.35 |
| Enterprise Value to Sales | 0.625 |
| Total Debt to Enterprise Value | 0.402 |
FDMT Efficiency
| Revenue/Employee | 434,739.796 |
| Income Per Employee | -714,841.837 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.151 |
FDMT Liquidity
| Current Ratio | 9.393 |
| Quick Ratio | 9.393 |
| Cash Ratio | 9.154 |
FDMT Profitability
| Gross Margin | 91.051 |
| Operating Margin | -187.242 |
| Pretax Margin | -164.43 |
| Net Margin | -164.43 |
| Return on Assets | -24.862 |
| Return on Equity | -27.573 |
| Return on Total Capital | -26.582 |
| Return on Invested Capital | -26.661 |
FDMT Capital Structure
| Total Debt to Total Equity | 4.235 |
| Total Debt to Total Capital | 4.063 |
| Total Debt to Total Assets | 3.778 |
| Long-Term Debt to Equity | 3.129 |
| Long-Term Debt to Total Capital | 3.002 |